The AI drug design cycle includes four phases: Design, Build, Test, and Learn. Generative AI creates novel drug candidates, which are produced by high throughput protein expression. Then evaluates their efficacy and developability. Data from these tests refine AI models, enhancing future designs. This iterative process improves efficiency and innovation in drug discovery.
GenScript's cell free protein synthesis system transforms traditional expression methods by enabling efficient protein production through in vitro synthesis. This innovative system, known for its speed, efficiency, flexibility, and cost-effectiveness, significantly reduces the time and expense associated with high-throughput expression. It serves as a powerful catalyst for early-stage AI-driven drug screening and model training.
5 Business Days till Results
Plasmids 100% Sequencing
1000 Samples per Day
600 Samples per Day
| Format | Volume | Timeline* | Deliverables |
|---|---|---|---|
| VHH - His | 1 ml (Target yield 10-200 μg) |
5 Business Days | Target Protein, CoA Report (A280, SDS-PAGE) |
| 5 ml
(Target yield 100-1000 μg) |
5 Business Days | ||
| Other format | 1/5 mL | Pre-evaluation |
Note:
*Sample# > 200 in one batch, may take extra time for production.
| Format | Volume | Timeline* | BLI Binding Report | Deliverable |
|---|---|---|---|---|
| VHH-His |
1mL Supernatant |
6 Business Days |
|
BLI Binding Report |
Note:
1.This service is only applicable to VHH-His, other formats need pre-evaluation.
2.Sample size > 96 may take extra time for BLI testing.
37 VHH-His 1mL Expression
*AI generated sequences
107 Mini Proteins 1mL Expression
*AI generated sequences
Conclusion:
From gene synthesis to antibody delivery starting at 8 BDs
Learn More
Yield up to gram, starting at 10 BDs
Learn More
Yield up to kg, from 6-7 weeks
Learn More
High expression level with ECACC-licensed CHO-K1 cell
Learn More
One-stop solution for antibody drug development
Learn More
